JORGE DANIEL SIERRA -LARA MARTINEZ

Dr. JORGE DANIEL SIERRA -LARA MARTINEZ

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
EAEmanuel Amezcua-Castillo
Emanuel Amezcua-Castillo
HGHéctor Gonzalez-Pacheco
Héctor Gonzalez-Pacheco
AMArturo Sáenz-San Martín
Arturo Sáenz-San Martín
PMPablo Méndez-Ocampo
Pablo Méndez-Ocampo
IMIván Gutierrez Moctezuma
Iván Gutierrez Moctezuma
LALuis M Amezcua-Guerra
Luis M Amezcua-Guerra
Atherosclerotic cardiovascular disease (CVD) remains the leading cause of mortality worldwide. While conventional risk factors have been studied and managed, CVD continues to pose a global threat. Risk scoring systems based on these factors have been developed to predict acute coronary syndromes and guide therapeutic interventions. However, traditional risk algorithms may not fully capture the complexities of individual patients. Recent research highlights the role of inflammation, particularly chronic low-grade inflammation, in the pathogenesis of coronary artery disease (CAD). C-reactive protein (CRP) is an inflammatory molecule that has demonstrated value as a predictive marker for cardiovascular risk assessment, both independently and in conjunction with other parameters. It has been incorporated into risk assessment algorithms, enhancing risk prediction and guiding therapeutic decisions. Pharmacological interventions with anti-inflammatory properties, such as statins, glucagon-like peptide-1 agonists, and interleukin-1 inhibitors, have shown promising effects in reducing both cardiovascular risks and CRP levels. This manuscript provides a comprehensive review of CRP as a marker of systemic inflammation in CAD. By exploring the current knowledge surrounding CRP and its implications for risk prediction and therapeutic interventions, this review contributes to the advancement of personalized cardiology and the optimization of patient care.

30 November 2021 in Global Heart
Verified
Journal Article
Open access
PDF file
HGHéctor Gonzalez-Pacheco
Héctor Gonzalez-Pacheco
DMDaniel Manzur-Sandoval
Daniel Manzur-Sandoval
RGRodrigo Gopar-Nieto
Rodrigo Gopar-Nieto
AÁAmada Álvarez-Sangabriel
Amada Álvarez-Sangabriel
CMCarlos Martínez-Sánchez
Carlos Martínez-Sánchez
AAAlexandra Arias-Mendoza
Alexandra Arias-Mendoza
Latin America has limited information about the full spectrum cardiogenic shock (CS) and its hospital outcome. This study sought to examine the temporal trends, clinical features and outcomes of patients with CS in a coronary care unit of single Mexican institution. This was a retrospective study of consecutive patients hospitalized with CS in a Mexican teaching hospital between 2006–2019. Patients were classified according to the presence or absence of acute myocardial infarction (AMI). Of 22,747 admissions, 833 (3.7%) exhibited CS. Among patients with AMI (n = 12,438), 5% had AMI–CS, and in patients without AMI (n = 10,309), 2.3% developed CS (non-AMI–CS). Their median age was 63 years and 70.5% were men. Cardiovascular risk factors were more frequent among the AMI–CS group, whereas a history of heart failure was greater in non-AMI–CS patients (70.1%). In AMI-CS patients, the median delay time was 17.2 hours from the onset of AMI symptoms to hospital admission. Overall, the median left ventricular ejection fraction (LVEF) was 30%. Patients with CS at admission showed end-organ dysfunction, evidenced by lactic acidosis, renal impairment, and elevated liver transaminases. Of the 620 AMI–CS patients, the main cause was left ventricular dysfunction in 71.3%, mechanical complications in 15.2% and right ventricular infarction in 13.5%. Among the 213 non-AMI–CS patients, valvular heart disease (49.3%) and cardiomyopathies (42.3%) were the most frequent etiologies. In-hospital all-cause mortality rates were 69.7% and 72.3% in the AMI–CS and non-AMI–CS groups, respectively. Among AMI–CS patients, renal dysfunction, diabetes, older age, depressed LVEF, absence of revascularization and the use of mechanical ventilation were independent predictors of in-hospital mortality. However, in the non-AMI–CS group, only low LVEF and high lactate levels proved significant. This study demonstrates differences in the epidemiology of CS compared to high-income countries; the high mortality reflects critically ill patients and the lack of contemporary effective therapies in the population studied.

20 April 2023 in Global Heart
Verified
Journal Article
Open access
PDF file
AAAlexandra Arias-Mendoza
Alexandra Arias-Mendoza
HGHéctor Gonzalez-Pacheco
Héctor Gonzalez-Pacheco
AÁAmada Álvarez-Sangabriel
Amada Álvarez-Sangabriel
RGRodrigo Gopar-Nieto
Rodrigo Gopar-Nieto
LRLaura Leticia Rodríguez-Chávez
Laura Leticia Rodríguez-Chávez
AAAlfredo Altamirano-Castillo
Alfredo Altamirano-Castillo
Background: Women are underrepresented in acute myocardial infarction (AMI) studies. Furthermore, there is scarce information regarding women with AMI in Latin America. Aims: To describe the presentation, clinical characteristics, risk factor burden, evidence-based care, and in-hospital outcome in a population of women with AMI admitted to a coronary care unit (CCU) in Mexico. Methods: Retrospective cohort study including patients with AMI admitted from January 2006 to December 2021 in a CCU. We identified patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). We described demographic characteristics, clinical variables, treatment, and in-hospital outcomes according to gender. Cox regression analysis was used to identify predictors of mortality. Results: Our study included 12,069 patients with AMI, of whom 7,599 had STEMI and 4,470 had NSTEMI. Women represented 19.6% of the population. Women had higher rates of hypertension, diabetes, stroke, and atrial fibrillation than men. For STEMI, women were less likely to receive reperfusion therapy (fibrinolysis; 23.7 vs. 28.5%, p < 0.001 and primary percutaneous coronary intervention (PCI); 31.2 vs. 35.1%, p = 0.001) and had more major adverse events than men: heart failure (4.2 vs. 2.5%, p = 0.002), pulmonary edema (3.4% vs. 1.7%, p < 0.001), major bleeding (2.1% vs. 1%, p = 0.002), stroke (1.3% vs. 0.6%, p = 0.008), and mortality (15.1% vs. 8.1%, p < 0.001). For NSTEMI, women were less likely to undergo coronary angiography or PCI and had more major bleeding and mortality. Multivariate Cox regression analysis revealed that females had an increase in mortality in STEMI and NSTEMI (HR 1.21, CI 1.01–1.47, p = 0.05 and HR 1.39, CI 1.06–1.81, p = 0.01). Conclusion: Real-world evidence from a hospital in a Latin American low- to middle-income country (LMIC) showed that women with AMI had more comorbidities, received less reperfusion treatment or invasive strategies, and had worse outcomes. In STEMI and NSTEMI, female gender represented an independent predictor of in-hospital mortality.

24 September 2025 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
FSFabio Solis-Jiménez
Fabio Solis-Jiménez
XEXimena Latapi-Ruiz Esparza
Ximena Latapi-Ruiz Esparza
HGHannah Priscila Guzman-Solorzano
Hannah Priscila Guzman-Solorzano
MVMonserrat Villalobos-Pedroza
Monserrat Villalobos-Pedroza
LMLuis Angel Morales-Villamil
Luis Angel Morales-Villamil
AAAlexandra Arias-Mendoza
Alexandra Arias-Mendoza
Purpose: Patients with coronary ectasia (CAE) have an increased risk of major cardiovascular events (MACE). Current preventive treatments are uncertain, with oral anticoagulants often prescribed based on limited retrospective studies. Our aim is to help address the question: what is the most appropriate treatment? Methods: Using a retrospective cohort of patients with an ACS and CAE in a single center in Mexico City, two groups were observed based on the treatment at discharge: dual antiplatelet therapy (group 1) and anticoagulation with either a VKA or a DOAC, regardless of antiplatelet therapy (group 2). The main outcome was MACE, which was a composite of all-cause mortality, reinfarction, and ischemic stroke at 4.5 years follow-up. Results: A total of 354 patients admitted for ACS and CAE were included. 228 (64.4%) patients were classified in the DAPT group and 126 (35.5%) in the anticoagulants group. The DAPT group had higher type 2 diabetes rates, NSTEMI presentation, and lower-grade ectasia. The anticoagulation group had higher STEMI presentation and higher-grade ectasia. The DAPT group had 33 (14.5%) events of MACE, whereas the anticoagulation group had 16 (13.1%) events. Anticoagulants were not associated with a risk reduction of the primary endpoint (HR 0.95; 95% CI, 0.47–1.54; p =  0.59), nor any of the individual components. Conclusion: This retrospective cohort study showed similar effectiveness between DAPT and anticoagulation in patients with ACS and CAE for preventing MACE, and lower bleeding risk. Further research is needed to identify optimal candidates for each antithrombotic regime. Graphical DAPT: double antiplatelet therapy, HR: hazard ratio

9 August 2022 in Coronary Artery Disease
Verified
Journal Article
Closed access
DADiego Araiza-Garaygordobil
Diego Araiza-Garaygordobil
AAAlexandra Arias-Mendoza
Alexandra Arias-Mendoza
JGJosé C. González-Gutiérrez
José C. González-Gutiérrez
JMJORGE DANIEL SIERRA -LARA MARTINEZ
JORGE DANIEL SIERRA -LARA MARTINEZ
DADiana L. Alfaro-Ponce
Diana L. Alfaro-Ponce
HGHéctor González-Pacheco
Héctor González-Pacheco

30 August 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
BABrianda Amezcua-Guerra
Brianda Amezcua-Guerra
LALuis M. Amezcua-Castillo
Luis M. Amezcua-Castillo
JGJazmín A. Guerra-López
Jazmín A. Guerra-López
KDKietseé A. Díaz-Domínguez
Kietseé A. Díaz-Domínguez
JGJosé Luis Sánchez Gloria
José Luis Sánchez Gloria
LALuis M Amezcua-Guerra
Luis M Amezcua-Guerra
Prompt diagnosis of ST-segment elevation myocardial infarction (STEMI) is essential for initiating timely treatment. MicroRNAs have recently emerged as biomarkers in cardiovascular diseases. This study aimed to evaluate the discriminatory capacity of serum microRNAs in identifying an ischemic origin in patients presenting with chest discomfort to the Emergency Department. The study included 98 participants (78 with STEMI and 20 with nonischemic chest discomfort). Significant differences in the expression levels of miR-133b, miR-126, and miR-155 (but not miR-1, miR-208, and miR-208b) were observed between groups. miR-133b and miR-155 exhibited 97% and 93% sensitivity in identifying STEMI patients, respectively. miR-126 demonstrated a specificity of 90% in identifying STEMI patients. No significant associations were found between microRNAs and occurrence of major adverse cardiovascular events (MACE). However, patients with MACE had higher levels of interleukin (IL)-15, IL-21, IFN-γ-induced protein-10, and N-terminal pro B-type natriuretic peptide compared to non-MACE patients. Overall, there were significant associations among the expression levels of microRNAs. However, microRNAs did not demonstrate associations with either inflammatory markers or cardiovascular risk scores. This study highlights the potential of microRNAs, particularly miR-133b and miR-126, as diagnostic biomarkers for distinguishing patients with STEMI from those presenting with nonischemic chest discomfort to the Emergency Department.